Journal Article

Effects of Recombinant Human Growth Hormone on Fat Distribution in Patients with Human Immunodeficiency Virus-Associated Wasting

Viva W. Tai, Morris Schambelan, Heather Algren, Clara Shayevich and Kathleen Mulligan

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 35, issue 10, pages 1258-1262
Published in print November 2002 | ISSN: 1058-4838
Published online November 2002 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/343051
Effects of Recombinant Human Growth Hormone on Fat Distribution in Patients with Human Immunodeficiency Virus-Associated Wasting

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

In light of current interest in recombinant human growth hormone (GH) as a treatment for fat distribution abnormalities, we retrospectively evaluated regional changes in fat and lean body mass in a subset of subjects who participated in randomized, double-blind, placebo-controlled trials of GH for treatment of wasting. Treatment with a pharmacologic dose of GH (0.1 mg/kg/day) resulted in significant and sustained increases in lean body mass and losses of fat in both the trunk and appendicular regions.

Journal Article.  2425 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.